- Conditions
- Onychomycosis
- Interventions
- Diode Laser Treatment
- Device
- Lead sponsor
- ConBio, a Cynosure Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 2
- States / cities
- New London, Connecticut • Westbrook, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2881–2904
of 13,629
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sexual Dysfunction, Physiological, Body Image, Libido; Loss, Aversion
- Interventions
- Hypnotic Relaxation Intervention (HRI), Vulvovaginal Atrophy (VVA)
- Other · Device
- Lead sponsor
- The University of Tennessee, Knoxville
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Skin Laxity
- Interventions
- Ulthera System Treatment
- Device
- Lead sponsor
- Ulthera, Inc
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, Healthy Subject, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Luminal A Breast Carcinoma, Luminal B Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Interventions
- Aspiration of Breast, Biospecimen Collection
- Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Breast Cancer
- Interventions
- interactive 3D tool, BREAST-Q Reconstruction Module, DQI, Ottawa Decision Regret Scale
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Herpes
- Interventions
- Versabase gel with sarracenia purpurea 20% liquid extract, placebo (versabase gel only)
- Other
- Lead sponsor
- Naturopaths International
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Flagstaff, Arizona
- Conditions
- Systemic Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Breast Cancer, Neoplasms, Breast
- Interventions
- Investigational Cancer Drug
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 30
- States / cities
- Chula Vista, California • Los Angeles, California • Poway, California + 24 more
- Conditions
- Erythematous (Type One) Rosacea
- Interventions
- V-101, vehicle
- Drug · Other
- Lead sponsor
- Vicept Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 7
- States / cities
- San Diego, California • Miami Beach, Florida • Louisville, Kentucky + 4 more
- Conditions
- Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
- Interventions
- Fulvestrant, Repotrectinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia
- Interventions
- CDX-1140, CDX-301, pembrolizumab, Chemotherapy
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more
- Conditions
- Actinic Keratosis
- Interventions
- Aminolevulinic Acid, Topical Solution Vehicle, BLU-U, Cryotherapy
- Drug · Device · Procedure
- Lead sponsor
- DUSA Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 8
- States / cities
- San Diego, California • Arlington Heights, Illinois • Carmel, Indiana + 4 more
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Interventions
- Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Panitumumab, Pembrolizumab
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Carol Fabian, MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 229 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Basal Cell Carcinoma, Keratosis Palmaris et Plantaris, Psoriasis
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1977 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pressure Ulcer, Soft Tissue Necrosis Lower Limb
- Interventions
- Negative Pressure Wound Therapy, Collagenase Ointment
- Device · Biological
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
- Interventions
- A166
- Drug
- Lead sponsor
- Klus Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 10
- States / cities
- Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more
- Conditions
- Breast Cancer, Adherence, Medication, Side Effect
- Interventions
- BETA-Text text messaging intervention
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Breast Cancer
- Interventions
- [18F]Flutemetamol, [18F]fluoro-2-deoxy-D-glucose (FDG), Functional Magnetic Resonance Imaging (fMRI)
- Drug · Diagnostic Test
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
- Interventions
- Palbociclib, Letrozole, Fulvestrant, Optional research biopsy, Goserelin, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional)
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Lincoln, Nebraska
- Conditions
- Choroiditis, Iridocyclitis, Iritis, Retinal Disease
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 4 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Psoriasis, Plaque Psoriasis
- Interventions
- EDP1815, Placebo
- Drug
- Lead sponsor
- Evelo Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 8
- States / cities
- Santa Rosa, California • Orlando, Florida • St. Petersburg, Florida + 5 more
- Conditions
- Atrophic Vaginitis
- Interventions
- Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream, Placebo Vaginal Cream
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 40 Years to 70 Years · Female only
- Enrollment
- 366 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Anakinra plus Standard of Care
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas